Enhancing Health System Initiatives: Utilizing Clinical Advances to Optimize the Diagnosis and Treatment of Prostate Cancer
The management of patients with castration-resistant prostate cancer (CRPC) has undergone enormous changes in the past 15 years. We now enjoy the benefit of 7 agents (plus Radium-223) to treat patients with metastatic CRPC (mCRPC). Moreover, we also recognize a new clinical diagnosis, nonmetastatic CRPC(nmCRPC), which is defined as a clinical state where patients, despite achieving castrate levels of testosterone with androgen deprivation therapy, exhibit progressive disease (rising prostate-specific antigen levels) with no evidence of radiographic metastases. As a newly defined disease state associated with a degree of clinical uncertainty, many clinicians face challenges managing patients with nmCRPC in practice. Recently completed and ongoing studies have established the role of antiandrogen receptor agents for treating patients with nmCRPC. Despite the promising results of these agents, many questions remain regarding their appropriate use. The activities in this initiative include a video presentation by an expert in prostate cancer research, which will provide a current overview of both mCRPC and nmCRPC. It also includes an Expert Panel discussion among 3 oncology specialists who review our current understanding of nmCRPC and the current clinical data for anti-AR therapies for nmCRPC in addition to discussing the practical implications of these agents in clinical practice. And finally, an online resource portal features numerous web-based and print resources as well guidelines to supplement the information included in these activities.
The goal of this program is for academic and community urologists, radiation and medical oncologists, oncologic surgeons, residents, fellows, nurse practitioners, physician assistants, nurses, and other allied healthcare professionals interested in the treatment and management of prostate cancer to better understand the context of both nm and mCRPC and to effectively use the respective therapies for these disease states.
This educational initiative is intended for academic and community urologists, radiation and medical oncologists, oncologic surgeons, residents, fellows, nurse practitioners, physician assistants, nurses, and other allied healthcare professionals interested in the treatment and management of prostate cancer. No prerequisites required.
After completing these activities, participants will demonstrate the ability to:
• DEFINE nmCRPC in the context of the Clinical States Model of prostate cancer.
• EVALUATE the clinical implications of current and emerging androgen receptor antagonist therapy for nmCRPC based on clinical trial data.
• ASSESS the practical implications of currently available therapies for mCRPC for appropriate treatment sequencing based on patient-specific factors.
• RECOGNIZE unmet needs and current clinical challenges associated with managing nmCRPC.
• EVALUATE clinical data on the use of androgen-receptor antagonists in nmCRPC.
• ANALYZE emerging literature on the influence initial therapy selection may have on subsequent treatment options and sequencing.
In support of improving patient care, MedStar Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) and the American Academy of PAs (AAPA), to provide continuing education for the healthcare team.
Credit Designation Statement
Activities in this initiative were planned by and for the healthcare team, and learners will receive interprofessional Continuing Education (IPCE) credits for learning and change.
Expert Panel Discussion:
.25 credits per case